Curio Genomics and Daicel Arbor Biosciences have launched the cloud-based bioinformatics platform myCurio, which resulted from a mult-year partnership between the firms. The platform consists of three modules. MyCurio Reports lets researchers review and visualize genome reference alignment, coverage, and variant calls for each sample; myCurio Insights enables them to interpret their complete dataset; and myCurio PowerTools provides bioinformaticians with configuration capabilities to optimize analyses.
Dolomite Bio launched a bioinformatics service, a single-cell RNA-sequencing analysis service accompanying its RNAdia kits. Available for purchase alongside the RNAdia kit, the service offers access to dedicated support from one of Dolomite Bio's bioinformaticians. Dolomite said it will accept sample sizes ranging from as little as one sample to as many as required by a specific research project.
Biodesix has launched GeneStrat NGS, a 52-gene blood-based tumor profiling test intended to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others. Sequencing results are further interrogated using PierianDx's variant interpretation knowledge database. Physicians receive a streamlined report with a 72-hour turnaround time.
GeneStrat NGS is also a component of a broader test package that Biodesix also recently launched, the IQLung Treatment Guidance Testing Strategy, which includes blood-based proteomic and genomic testing workflows. The company said it plans to add tests to the IQLung portfolio in the future.
Amoy Diagnostics and Premia have launched the AmoyDx Pan Lung Cancer PCR Panel in Japan as a reimbursed companion diagnostic for multiple anti-cancer agents. The panel was conceived by AmoyDx, who also manufactures it, and developed in Japan by Premia. It uses real-time PCR to evaluate 11 driver genes. In Japan, the use of five driver genes on the panel has been approved as a companion diagnostic for 10 targeted therapies for non-small cell lung cancer.
Akoya Biosciences has launched the PhenoCycler-Fusion system for high-speed imaging of slides at single-cell and sub-cellular resolution. The platform combines the strengths of the firm's automated, high-multiplex cycling platform PhenoCycler (previously branded as Codex) and its high-speed imaging platform PhenoImager (previously branded as Phenoptics) into an integrated workflow. In addition to protein biomarkers, the system can detect RNA, using RNAScope assays developed in collaboration with Bio-Techne. It can detect more than 100 markers for deep spatial phenotyping and map every cell across a tissue section, including from FFPE slides. It is capable of processing more than 100 slides per week, according to the company.
Congenica has expanded its clinical consulting services by introducing a "sample to report" service. The UK-based company said that the new offering will support clinical laboratories with constrained capacity by connecting them with sequencing partners to conduct panel, whole-exome, and whole-genome sequencing. Congenica can then perform data analysis and clinical interpretation, and, where allowed by law, sign off on reports on behalf of its clients.
Lucence has launched an expanded version of its flagship LiquidHallmark liquid biopsy assay that includes both cell-free DNA and RNA profiling. The combined panel, available for US customers as a laboratory-developed test, includes cfRNA profiling of 27 actionable and emerging gene fusions and cfDNA profiling of mutations in 80 genes and fusions in 10 genes. The assay is powered by AmpliMark, the company’s proprietary amplicon-based sequencing technology, which uses molecular barcode and error-correction technology.
Phase Genomics has launched the OncoTerra platform for precision oncology research. A single assay offers genome-wide detection of a wide range of chromosomal abnormalities without the need for actively dividing cells, high molecular weight DNA extraction, or a high starting volume. The platform is powered by Phase Genomics' ultra-long-range sequencing technology that captures physical proximity data from genomic DNA sequences. These data are then analyzed via proprietary machine learning tools to detect diverse chromosomal aberrations and rearrangements, including tumorigenic rearrangements, that cause and characterize diseases. Phase said the platform is most effective on formalin-fixed paraffin-embedded samples, enabling oncology applications.
Biotium has released the Ember500 RNA Prestain Loading Dye, which is more sensitive than conventional prestaining with ethidium bromide (EtBr) and is compatible with blue LED gel imagers, unlike EtBr. The prestain also includes formamide as well as electrophoresis tracking dyes, allowing sample denaturing, loading, tracking, and staining in a single step. In addition, Ember500 stains both RNA and DNA, allowing the detection of contaminating genomic DNA in purified RNA samples, Biotium said. The prestain will be supplied at a 2X concentration and will be available in 4 x 1 mL and 1 x 250 uL sizes priced at $350 and $60, respectively. Free samples will be available for a limited time, the company added.
Centogene has released CentoCloud, a software-as-a-service platform for the decentralized analysis, interpretation, and reporting of genomic variants linked to rare diseases. CentoCloud uses next-generation sequencing data from laboratories for automated, curated, bioinformatic analysis and AI-based variant prioritization and classification, followed by reporting. Results from consented data will also be used to augment Centogene's rare disease-focused bio/databank.